{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:00:52Z","timestamp":1793660452277,"version":"4.5.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>CD73, a recently discovered immune checkpoint, catalyzes the conversion of AMP to adenosine, thereby suppressing anti-tumor immune responses.CD8<jats:sup>+<\/jats:sup> T cells play a critical role in the immune response against cancer, yet their functionality can be modulated by various factors within the tumor microenvironment. In this study, we focus on identifying and characterizing CD73<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T cells in the peripheral blood of patients with diffuse large B-cell lymphoma (DLBCL), aiming to elucidate their functional and phenotypic roles in tumor immunity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using flow cytometry, we analyzed the expression of inhibitory receptors (e.g., PD-1, TIM-3) and activating markers (e.g., CD25, CD69) on CD73<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T cells compared to CD73<jats:sup>\u2212<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T cells. <jats:italic>In vitro<\/jats:italic> functional assays were conducted to assess their cytotoxic activity against tumor cells, including cytokine production and tumor cell killing capacity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CD73<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T cells exhibited a distinct immunophenotypic profile, characterized by reduced expression of inhibitory receptors and enhanced cytotoxic activity compared to their CD73<jats:sup>\u2212<\/jats:sup> counterparts. These cells demonstrated higher levels of effector molecules (e.g., IFN-\u03b3, TNF-\u03b1) and lower exhausted markers. The findings suggest that CD73<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T cells may retain stronger anti-tumor potential.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study highlights CD73<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T cells as a unique functional subset with potential therapeutic relevance in DLBCL. Their reduced exhaustion and heightened cytotoxicity position them as promising targets for immunotherapy strategies. However, the dual role of CD73 in adenosine-mediated immunosuppression warrants further investigation to reconcile its pro-tumorigenic effects with the observed anti-tumor activity of CD73<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T cells. Our findings deepen the understanding of CD8<jats:sup>+<\/jats:sup> T cell heterogeneity in DLBCL and emphasize the need for mechanistic studies to explore CD73\u2019s context-dependent functions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1526772","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:49:44Z","timestamp":1746186584000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["CD73+CD8+ T cells define a subset with anti-tumor potential in DLBCL patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Lingyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongbing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2133.1993.tb00187.x","article-title":"Herpes simplex virus infection associated with bullous pemphigoid","volume":"128","author":"Sassolas","year":"1993","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1182\/blood.2019002395","article-title":"Avadomide monotherapy in relapsed\/refractory DLBCL: safety, efficacy, and a predictive gene classifier","volume":"135","author":"Carpio","year":"2020","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3390\/cells13121057","article-title":"Tumour microenvironment: the general principles of pathogenesis and implications in diffuse large B cell lymphoma","volume":"13","author":"Sinkarevs","year":"2024","journal-title":"Cells"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1084\/jem.20150598","article-title":"High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival","volume":"213","author":"Utzschneider","year":"2016","journal-title":"J Exp Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","article-title":"Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma","volume":"596","author":"Oliveira","year":"2021","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science (New York, NY)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","article-title":"Targeting CD73 to augment cancer immunotherapy","volume":"53","author":"Roh","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/BF01919318","article-title":"Accumulation of purine catabolites in solid tumors exposed to therapeutic hyperthermia","volume":"52","author":"Busse","year":"1996","journal-title":"Experientia"},{"key":"ref15","first-page":"2602","article-title":"The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine","volume":"57","author":"Blay","year":"1997","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1038\/onc.2010.292","article-title":"Extracellular adenosine triphosphate and adenosine in cancer","volume":"29","author":"Stagg","year":"2010","journal-title":"Oncogene"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fimmu.2016.00109","article-title":"A metabolic immune checkpoint: adenosine in tumor microenvironment","volume":"7","author":"Ohta","year":"2016","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1158\/0008-5472.CAN-09-3109","article-title":"CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression","volume":"70","author":"Jin","year":"2010","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1073\/pnas.0908801107","article-title":"Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis","volume":"107","author":"Stagg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e2302498","DOI":"10.1002\/advs.202302498","article-title":"Tumor microenvironment responsive CD8+ T cells and myeloid-derived suppressor cells to trigger CD73 inhibitor AB680-based synergistic therapy for pancreatic Cancer","volume":"10","author":"Chen","year":"2023","journal-title":"Adv Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/ijc.31534","article-title":"Specific blockade CD73 alters the \"exhausted\" phenotype of T cells in head and neck squamous cell carcinoma","volume":"143","author":"Deng","year":"2018","journal-title":"Int J Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-10-1544","article-title":"CD73: a novel target for cancer immunotherapy","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2217\/imt-2018-0200","article-title":"CD73: an emerging checkpoint for cancer immunotherapy","volume":"11","author":"Chen","year":"2019","journal-title":"Immunotherapy"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1172\/JCI79380","article-title":"Loss of CD73-mediated actin polymerization promotes endometrial tumor progression","volume":"126","author":"Bowser","year":"2016","journal-title":"J Clin Invest"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3802\/jgo.2012.23.4.274","article-title":"Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration","volume":"23","author":"Oh","year":"2012","journal-title":"J Gynecol Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"785461","DOI":"10.1155\/2015\/785461","article-title":"CD73 predicts favorable prognosis in patients with nonmuscle-invasive urothelial bladder Cancer","volume":"2015","author":"Wettstein","year":"2015","journal-title":"Dis Markers"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e142843","DOI":"10.1172\/jci.insight.142843","article-title":"Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC","volume":"7","author":"Tu","year":"2022","journal-title":"JCI Insight"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/s41401-021-00840-z","article-title":"Therapeutic efficacy and mechanism of CD73-TGF\u03b2 dual-blockade in a mouse model of triple-negative breast cancer","volume":"43","author":"Xing","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-019-0728-3","article-title":"Downregulation of CD73 associates with T cell exhaustion in AML patients","volume":"12","author":"Kong","year":"2019","journal-title":"J Hematol Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1189\/jlb.0113018","article-title":"Decreased frequency of CD73+CD8+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustion","volume":"94","author":"T\u00f3th","year":"2013","journal-title":"J Leukoc Biol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/eji.202048626","article-title":"CD8+ CD73+ T cells in the tumor microenvironment of head and neck cancer patients are linked to diminished T cell infiltration and activation in tumor tissue","volume":"50","author":"Panigrahi","year":"2020","journal-title":"Eur J Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1526772\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:49:45Z","timestamp":1746186585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1526772\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":33,"alternative-id":["10.3389\/fmed.2025.1526772"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1526772","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"article-number":"1526772"}}